Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Psychiatry Investigation ; : 2-8, 2020.
Article | WPRIM | ID: wpr-832523

ABSTRACT

Psychiatric diseases are the manifestations that result from the individual’s genetic structure, physiology, immunology and ways of coping with environmental stressors. The current psychiatric diagnostic systems do not include any systematic characterization in regard to neurobiological processes that reveal the clinical picture in individuals who got psychiatric diagnosis. It is obvious that further research in different areas is needed to understand the psychopathology. The problems in the functions of immune system and the correlation of neuroinflammatory processes with psychiatric disorders have been one of the main research topics of psychiatry in recent years and have contributed to our understanding of psychopathology. Recent advances in the fields of immunology and genetics as well as rapidly increasing knowledge on the effects of immunological processes on brain functions have drawn attention to the correlations between psychiatric disorders and immune system dysfunctions. There are still unfilled gaps in the biology, pathophysiology, and treatment of major depressive disorder, which is quite prevalent among the psychiatric disorders, can lead to significant disability, and frequently has a recurrent course. It appears that low-grade chronic neuroinflammation plays a key role in forming a basis for the interaction between psychological stress, impaired gut microbiota and major depressive disorder. In this review, the role of neuroinflammation in the etiopathogenesis of depression and the mechanism of action of the gut-brain axis that leads to this are discussed in the light of current studies.

2.
Clinical Psychopharmacology and Neuroscience ; : 114-117, 2018.
Article in English | WPRIM | ID: wpr-739453

ABSTRACT

Bipolar affective disorder (BD) diagnosis and initiation of appropriate treatment are often delayed, and this is associated with poorer outcomes, such as rapid cycling or cognitive decline. Therefore, identifying certain warning signs of a probable successive episode during the inter-episode phase is important for early intervention. We present the retrospective data of three cases of BD. Our first case had a history of alcohol use disorder (AUD), where he drank in a dipsomaniac manner, and the other two cases had dipsomaniac alcohol use before their manic attacks, and none of them had any AUD after the mood episode was over. Two brothers also had hypertensive episodes during the manic attacks. None of the cases reported increased fluid intake when they were euthymic. We suggest that polydipsia in BD may be a warning sign of an upcoming manic episode, especially in those patients with AUD. Polydipsia in BD may be caused or facilitated by a combination of hyperdopaminergic activity, hypothalamic dysfunction, and dysregulated renin-angiotensin system. To be able to prevent new episodes, a patient’s drinking habits and change in fluid intake should be asked at every visit. Those patients with a history of alcohol abuse should especially be informed about polydipsia and manic episode association.


Subject(s)
Humans , Alcoholism , Binge Drinking , Bipolar Disorder , Comorbidity , Diagnosis , Drinking , Early Intervention, Educational , Mood Disorders , Polydipsia , Renin-Angiotensin System , Retrospective Studies , Siblings
3.
Korean Journal of Family Medicine ; : 259-259, 2016.
Article in English | WPRIM | ID: wpr-212275

ABSTRACT

No abstract available.


Subject(s)
Hyperamylasemia , Sertraline
4.
Korean Journal of Family Medicine ; : 359-359, 2016.
Article in English | WPRIM | ID: wpr-137665

ABSTRACT

No abstract available.


Subject(s)
Carcinoembryonic Antigen , Citalopram
5.
Korean Journal of Family Medicine ; : 359-359, 2016.
Article in English | WPRIM | ID: wpr-137664

ABSTRACT

No abstract available.


Subject(s)
Carcinoembryonic Antigen , Citalopram
6.
Clinical Psychopharmacology and Neuroscience ; : 231-237, 2016.
Article in English | WPRIM | ID: wpr-108201

ABSTRACT

Fecal microbiota transplantation has a 1700-year history. This forgotten treatment method has been put into use again during the last 50 years. The interest in microbiota-gut-brain axis and fecal microbiota transplantation is rapidly increasing. New evidence is obtained in the etiopathogenesis of neuropsychiatric disorders. There is a large number of experimental and clinical researches in the field of gut-brain axis. There is limited information on fecal microbiota transplantation. Despite this, initial results are promising. It is commonly used in the treatment of gastrointestinal diseases such as Clostridium difficile infection, Crohn's disease, ulcerative colitis. It is also experimentally used in the treatment of metabolic and autoimmune diseases. There are case reports that it is effective in the treatment of autism, Parkinson's disease, multiple sclerosis, chronic fatigue syndrome and irritable bowel syndrome. Its implementation is easy, and it is a cheap and reliable treatment method. However, the long-term risks are unknown. Additionally, standard application protocols have not yet been established. There are a lot of questions to be answered. A university in Turkey has got official permission this year, and started to apply fecal microbiota transplantation. In this review, neuropsychiatric areas of use of fecal microbiota transplantation have been discussed in the light of the current information.


Subject(s)
Autistic Disorder , Autoimmune Diseases , Clostridioides difficile , Colitis, Ulcerative , Crohn Disease , Fatigue Syndrome, Chronic , Fecal Microbiota Transplantation , Gastrointestinal Diseases , Immune System , Irritable Bowel Syndrome , Methods , Multiple Sclerosis , Neurology , Parkinson Disease , Turkey
7.
Annals of Dermatology ; : 334-335, 2015.
Article in English | WPRIM | ID: wpr-93838

ABSTRACT

No abstract available.


Subject(s)
Erythema Multiforme
8.
Clinical Psychopharmacology and Neuroscience ; : 239-244, 2015.
Article in English | WPRIM | ID: wpr-197174

ABSTRACT

The gut microbiota is essential to human health and the immune system and plays a major role in the bidirectional communication between the gut and the brain. Based on evidence, the gut microbiota is associated with metabolic disorders such as obesity, diabetes mellitus and neuropsychiatric disorders such as schizophrenia, autistic disorders, anxiety disorders and major depressive disorders. In the past few years, neuroscientific research has shown the importance of the microbiota in the development of brain systems. Recent studies showed that the microbiota could activate the immune and central nervous systems, including commensal and pathogenic microorganisms in the gastrointestinal tract. Gut microorganisms are capable of producing and delivering neuroactive substances such as serotonin and gamma-aminobutyric acid, which act on the gut-brain axis. Preclinical research in rodents suggested that certain probiotics have antidepressant and anxiolytic activities. Effects may be mediated via the immune system or neuroendocrine systems. Herein, we present the latest literature examining the effects of the gut microbiota on depression.


Subject(s)
Humans , Anxiety Disorders , Axis, Cervical Vertebra , Brain , Central Nervous System , Depression , Depressive Disorder, Major , Diabetes Mellitus , gamma-Aminobutyric Acid , Gastrointestinal Tract , Immune System , Microbiota , Neurosecretory Systems , Obesity , Probiotics , Rodentia , Schizophrenia , Serotonin
SELECTION OF CITATIONS
SEARCH DETAIL